EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Companyâs products are based on two proprietary platform technologies: EyeGateâs first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (âCMHA-Sâ), a modified form of the natural polymer hyaluronic acid (âHAâ), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGateâs second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGateâs proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications. Source
No articles found.
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...
Anthera Pharmaceuticals, Inc., a development st...
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company fo...
Portola Pharmaceuticals is a global, commercial...
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
Natureâs Sunshine Products (NASDAQ:NATR), a leading natural health and wellness ...
Natureâs Sunshine Products (NASDAQ:NATR), a l...
Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...
Omeros is a commercial-stage biopharmaceutical ...
We are a patient-centric, clinical-stage biopharmaceutical company dedicated to br...
We are a patient-centric, clinical-stage biopha...
Join the National Investor Network and get the latest information with your interests in mind.